Eplerenone (INN) /ɛpˈlɛrənoʊn/ is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is similar to the diuretic spironolactone though it is much more selective for the mineralocorticoid receptor in comparison (i.e. does not possess any antiandrogen progestogen or estrogenic effects) and is specifically marketed for reducing cardiovascular risk in patients following myocardial infarction. It is marketed by Pfizer under the trade name Inspra.
This page contains content from the copyrighted Wikipedia article "Eplerenone"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
